[The effectiveness of monoamine oxidase inhibitors in treatment-resistant depressive disorders in clinical practice; a retrospective open-label study]

Monoamine oxidase (mao)-inhibitors are often prescribed in patients suffering from treatment-resistant depression, but the evidence of its effectiveness in this type of depression is limited: a restricted amount of similar studies describes response-rates of 12-75%.
AIM: To get more insight in the effectiveness of mao-inhibitors in treatment-resistant depression in clinical practice.
METHOD: We investigated medical files of patients with a uni- or bipolar, treatment-resistant depression and looked at the difference in score on the Inventory of Depressive Symptomatology - Self Report (ids-sr) before and after 3 months of treatment with a mao-inhibitor. After that, we investigated how often patients achieved remission, response, partial response, no response or drop-out due to of side-effects.
RESULTS: The included 17 patients achieved a mean decrease of 8.6 (sd:15.1) points, which corresponded with a decrease of 16.8% (p = 0.032). One patient (6%) achieved remission, 2 patients (12%) achieved response, 5 patients (29%) had partial response and 7 patients (41%) did not respond at all. Three patients (18%) quitted because of side-effects.
CONCLUSION: The results of this and similar studies are modest and ask for critical thinking and critical prescribing of mao-inhibitors, because of the possibly limited effectiveness in treatment-resistant depressions.

Similar articles

Schulte PFJ, Nolen WA. Schulte PFJ, et al. Tijdschr Psychiatr. 2020;62(6):502-505. Tijdschr Psychiatr. 2020. PMID: 32583871 Dutch.

Gudde A, van der Meij A, Spijker J. Gudde A, et al. Tijdschr Psychiatr. 2019;61(7):498-503. Tijdschr Psychiatr. 2019. PMID: 31372971 Review. Dutch.

Köhler S, Stöver LA, Bschor T. Köhler S, et al. Fortschr Neurol Psychiatr. 2014 Apr;82(4):228-36; quiz 237-8. doi: 10.1055/s-0034-1365945. Epub 2014 Apr 7. Fortschr Neurol Psychiatr. 2014. PMID: 24710679 Review. German. No abstract available.

Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM. Nolen WA, et al. Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Clin Neuropharmacol. 1993. PMID: 8313400 Review.

Schipper P, Vanmolkot L, Peeters FP. Schipper P, et al. Tijdschr Psychiatr. 2016;58(12):886-890. Tijdschr Psychiatr. 2016. PMID: 27976787 Review. Dutch.